Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025

Core Viewpoint - Smith+Nephew is showcasing advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting, highlighting innovative technologies such as Spatial Surgery and the CARTIHEAL AGILI-C Cartilage Repair Implant [1][2]. Group 1: Innovations in Sports Medicine - The company introduces Spatial Surgery, a new category in arthroscopic surgical innovation, featuring the TESSA Spatial Surgery System, which combines personalized operative planning with real-time tracking and augmented reality guidance [1]. - The CARTIHEAL AGILI-C Cartilage Repair Implant is FDA approved and aims to evolve the cartilage repair landscape, allowing treatment for patients previously without access to such procedures [2]. - Clinical studies show that patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee function, pain relief, and mobility improvements over a four-year period [3]. Group 2: Clinical Outcomes and Efficacy - The CARTIHEAL AGILI-C Implant demonstrated a significantly lower risk of total knee arthroplasty (TKA) or osteotomy at four years compared to the surgical standard of care [3]. - The REGENETEN Bioinductive Implant has shown clinical superiority in rotator cuff repair, with results surpassing current standards of care and increasing usage in various tendon injuries [4]. - The REGENETEN Implant has been used in over 150,000 patients, resulting in a 3x reduction in the risk of re-tear in a randomized controlled trial versus standard repair alone [7]. Group 3: Company Overview - Smith+Nephew operates in approximately 100 countries and generated annual sales of $5.8 billion in 2024, focusing on the repair, regeneration, and replacement of soft and hard tissue [10]. - The company is a constituent of the FTSE100 and aims to restore patients' bodies and self-belief through innovative medical technologies [9].